AMBU B Share Price Performance
DKK 0
-104.30 (-100.00%)
Price DKK 0
Fair ValueDKK 138.00
Share Pricen/a
Narrative Update • May 19
Ambu A/S Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 14 Fair Values set on narratives written by author
AMBU B Community Narratives
AN
Fair Value
·Fair Value DKK 138 52.2% undervalued intrinsic discount
Aging Global Population And Healthcare Digitalization Will Expand Single-Use Endoscopy
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value DKK 88.8 25.7% undervalued intrinsic discount
Expansion Of Single-use Endoscopy Will Improve Hospital Efficiency
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
Fair Value
·Fair Value DKK 78 15.4% undervalued intrinsic discount
Rising Costs, Stricter Rules And Rivals Will Limit Market Prospects
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Expansion Of Single-use Endoscopy Will Improve Hospital Efficiency
Hospitals are looking for safer, faster procedures, and Ambu is betting big on disposable endoscopy tools to meet that demand. Find out what could power years of growth—and what competition, regulation, or costs could do to slow it down.Read more
AN
DKK 88.8
25.7% undervalued intrinsic discount
Fair Value
Revenue
11.59% p.a.
Profit Margin
13.44%
Future PE
23.1x
Price in 2029
DKK 105.1
Aging Global Population And Healthcare Digitalization Will Expand Single-Use Endoscopy
Key Takeaways Broad adoption of Ambu's single-use devices across departments and growing endoscopy demand are poised to outpace revenue and margin expectations. Shifting manufacturing to Mexico and digital healthcare integration uniquely position Ambu for margin expansion and premium service opportunities amid tightening infection control regulations.Read more
AN
DKK 138
52.2% undervalued intrinsic discount
Fair Value
Revenue
13.13% p.a.
Profit Margin
15.33%
Future PE
33.88x
Price in 2029
DKK 164.3
Rising Costs, Stricter Rules And Rivals Will Limit Market Prospects
Key Takeaways Intensifying pricing pressures and regulatory hurdles are set to challenge revenue growth and profitability for Ambu's single-use endoscopes. Advances in competing technologies and strong market competition threaten the long-term relevance and sales potential of Ambu's core product lines.Read more
AN
DKK 78
15.4% undervalued intrinsic discount
Fair Value
Revenue
10.15% p.a.
Profit Margin
13.37%
Future PE
23.28x
Price in 2029
DKK 90.82
Trending Discussion
Recently Updated Narratives
AN
AMBU B: Lower P/E Expectations Will Support Future Upside Repricing
Fair Value: DKK 88.8 25.7% undervalued intrinsic discount
6 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AMBU B: Higher Growth And Margins Are Expected To Support Future Upside
Fair Value: DKK 138 52.2% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AMBU B: Higher Risk Premium And Margin Pressure Will Reshape Share Outlook
Fair Value: DKK 78 15.4% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Ambu A/S Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 26, 2026
- 1.80
- 59.98%
- 7.81%
- 0.3%
About AMBU B
- Founded
- 1937
- Employees
- 5200
- CEO
- WebsiteView website
Ambu A/S, together with its subsidiaries, researches, develops, manufactures, markets, and sells medical technology solutions in North America, Europe, and internationally. The company offers endoscopy products, including bronchoscopes, video laryngoscopes, rhinolaryngoscopes, duodenoscopes, gastroscopes, cystoscopes, ureteroscopes, and displaying and processing units; neurology products, such as EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products; and cardiology products comprising ECG electrodes. It also provides airway management and anaesthesia products, which include double and single lumen tubes, endobronchial blockers, laryngeal and face masks, breathing bags, and resuscitators. In addition, the company offers emergency care and training products, such as extrication collars and ALS and BLS training manikins, as well as mobile workstations, IOMs, and patient monitoring and diagnostics devices. Ambu A/S was founded in 1937 and is headquartered in Ballerup, Denmark.
